Letterlife logotype

Precision health for ADHD

Letterlife is the first data driven precision health tool that allow girls and women with ADHD to visualize the interplay of hormones, ADHD-symptoms, and everyday lifestyle across the female lifespan. By tracking hormonal fluctuation during the menstrual cycle, effects of hormonal contraceptives or replacement treatment, and real-life relevant outcomes Letterlife enables girls and women and health care professionals to tailor individualized, evidence-based, and effective pharmacological treatment and self-care according to individual ADHD-profile and personal goals. The overall aim is to decrease time from early symptoms to diagnosis, ensure access to adequate health care interventions, empower self-efficacy, and encourage selfcare, for girls and women with ADHD.

Letterlife provide a data driven, gender informed foundation for the shared decision making in standard of care for ADHD. The unique technology link individualized automated and self-recorded data to population-based health care registries, enabling woman to create a individual prediction model to navigate the complex interplay between physical, mental and reproductive health.

See more presentations at our YouTube account.

Become a Beta User

We are busy developing Letterlife together with lead patient users, patient organizations, researchers’ clinicians. Every step of the way will be assessed and evaluated in scientific studies, led by our international research team and scientific advisory board. You can join our beta user group and take part in the co-creation of Letterlife! We invite girls and women with ADHD, ADHD-like symptoms, or comorbidity common in ADHD (i.e., depression, anxiety, PMS/PMDS, eating disorders) as well as health care professionals working in psychiatry, primary care, female health and youth centers.

Females with ADHD are diagnosed 4 years later than men

Equal, evidence based, and timely interventions are at the core of sustainable and effective health care. However, girls and women with ADHD are a substantial and severely underserved group, showing severe comorbidity, polypharmacy, and considerable health care utilization.

Despite a growing literature showing that predictable, hormonal fluctuations across the female reproductive life is associated with adverse physical, mental, and reproductive health outcomes, standard of care continue to disregard biology, imprudently accepting the male brain as the norm.

Built by Patients and their Doctors

App on iPhone

Letterlife, co-developed in collaboration with an expert panel of lead patient users, patient organizations, clinicians, and researchers, bears the potential to decrease time from symptom to diagnosis, decrease polypharmacy and multimorbidity, improve quality of medical decision-making, enhance compliance to adequately tailored pharmacological treatment, and encourage safe and effective self-care and in female ADHD.

  • Powered by personal data
  • Cost and resource effective
  • Saves time, money, and lives

Scientific studies

The Letterlife research project, lead by senior researchers Lotta Borg Skoglund MD PhD and Helena Kopp Kallner MD PhD aims to evaluate how data driven and individual real-life information can improve precision medicine, tailor effective standard of care and encourage self-care for girls and women with ADHD. Our long-term goal is to close the health gaps between female and male mental health. Critical for attaining this goal is to minimize diagnostic delay, decrease polypharmacy, and mitigate multimorbidity. This is done by targeting real-life relevant lifestyle factors, hormonal fluctuation and by tailoring pharmacological treatment and contraceptive counselling, keeping the individual cognitive profile in mind, ensuring access to appropriate health care for girls and women ADHD.

Study 1 & 2

Studies 1 & 2 are designed to explore the needs and existing barriers to adequate health care within the two main target groups (females with ADHD and health care professionals). Semi structured interviews based on a preconceived interview guide is performed with 30 healthcare professionals (physicians, nurses, midwifes and psychologists) and 45 females (aged 15 and over) with ADHD. The questions explore knowledge on, and specific challenges in; screening and assessment for female ADHD, gender specific prescription patterns, doses, adverse effects, compliance and adverse effects of ADHD-medication, hormonal contraceptives, and hormone replacement therapy.

Study 3 & 4

Studies 3 & 4 will explore if the digital tool Letterlife, developed in collaboration with an expert panel of lead patient users, patient organizations, and clinicians can a) decrease time from symptom to diagnosis and treatment in females with ADHD, b) improve quality of medical decision-making in standard of care, c) increase compliance to adequately titrated treatment medication d)encourage self-care and e) decrease risk for multimorbidity and polypharmacy in female ADHD.

Letterlife carries a real potential of changing lives in generations to come!

Helena Kopp Kallner

Adjunct professor of Obstetrics & Gynecology Karolinska Institute, Stockholm

This tool breaks new ground in a field of research that has been neglected for too long.

Anki Sandberg

President Riksförbundet Attention

Supporting individuals in finding what truly works for them - this is the future!

Sara Riggare

Personal Science expert